204 related articles for article (PubMed ID: 29110548)
1. New targets and therapies for gastrointestinal stromal tumors.
Wozniak A; Gebreyohannes YK; Debiec-Rychter M; Schöffski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1117-1129. PubMed ID: 29110548
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for the treatment of gastrointestinal stromal tumour.
Kasireddy V; von Mehren M
Expert Opin Emerg Drugs; 2017 Dec; 22(4):317-329. PubMed ID: 29183145
[TBL] [Abstract][Full Text] [Related]
3. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
Koseła-Paterczyk H; Rutkowski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
[TBL] [Abstract][Full Text] [Related]
4. Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.
Sankhala KK
Expert Opin Investig Drugs; 2017 Apr; 26(4):427-443. PubMed ID: 28267385
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for the treatment of gastrointestinal stromal tumors.
Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
7. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
8. Translational insights into gastrointestinal stromal tumor and current clinical advances.
Hemming ML; Heinrich MC; Bauer S; George S
Ann Oncol; 2018 Oct; 29(10):2037-2045. PubMed ID: 30101284
[TBL] [Abstract][Full Text] [Related]
9. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE
Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
11. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
Xu J; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353
[TBL] [Abstract][Full Text] [Related]
12. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
13. Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.
Alturkmani HJ; Pessetto ZY; Godwin AK
Expert Opin Investig Drugs; 2015; 24(8):1045-58. PubMed ID: 26098203
[TBL] [Abstract][Full Text] [Related]
14. Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
Kondo T
Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal stromal tumors: molecular markers and genetic subtypes.
Barnett CM; Corless CL; Heinrich MC
Hematol Oncol Clin North Am; 2013 Oct; 27(5):871-88. PubMed ID: 24093165
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.
Vadakara J; von Mehren M
Hematol Oncol Clin North Am; 2013 Oct; 27(5):905-20. PubMed ID: 24093167
[TBL] [Abstract][Full Text] [Related]
17. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic agents in gastrointestinal stromal tumours.
Falkenhorst J; Hamacher R; Bauer S
Curr Opin Oncol; 2019 Jul; 31(4):322-328. PubMed ID: 31033566
[TBL] [Abstract][Full Text] [Related]
19. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
20. Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.
Blay JY; Casali PG; Dei Tos AP; Le Cesne A; Reichardt P
Oncology; 2015; 89(1):1-13. PubMed ID: 25720422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
